Live Breaking News & Updates on Mariana cota stirner

Stay updated with breaking news from Mariana cota stirner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment

By Paul Ziobro AbbVie and Genmab said Tuesday that a clinical trial for a bispecific antibody to treat a form of non-Hodgkin's lymphoma would need further...

Paul-ziobro , Mariana-cota-stirner , Article-normal , Biotechnology-services , Pharmaceuticals , Healthcare-life-sciences , Biopharmaceuticals , New-products-services , Research-development , Corporate-industrial-news , Products-services

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

Mariana-cota-stirner , Dlbcl , Epcoritamab , Non-hodgkin-lymphoma , Crs , Bispecific-antibody , Subcutaneous ,

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...

United-states , Japan , Mariana-cota-stirner , Hematol-hemoter , Exchange-commission , Instagram , Us-inc , Youtube , Facebook , Data-from-the-observational-national-lymphocare-study , Linkedin , Twitter

AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in...

Germany , Melbourne , Victoria , Australia , Ludwigshafen , Rheinland-pfalz , German , Mariana-cota-stirner , Arnonp-kater , John-seymour , Othman-al-sawaf , Venclyxto-sm

Venetoclax Combinations Have Sustained Long-term Benefits for Relapsed, Refractory Chronic Lymphocytic Leukemia

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Melbourne , Victoria , Australia , Germany , German , Venclexta-venclyxto , Mariana-cota-stirner , Othman-al-sawaf , John-seymour , University-hospital-cologne , Peter-maccallum-cancer-center , Hematology-department